Perilous Reversal Stock: Sangamo BioSciences (SGMO)

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Trade-Ideas LLC identified Sangamo BioSciences ( SGMO) as a "perilous reversal" (up big yesterday but down big today) candidate. In addition to specific proprietary factors, Trade-Ideas identified Sangamo BioSciences as such a stock due to the following factors:

  • SGMO has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $13.9 million.
  • SGMO has traded 64,995 shares today.
  • SGMO is down 3.2% today.
  • SGMO was up 5.6% yesterday.

EXCLUSIVE OFFER: Get the inside scoop on opportunities in SGMO with the Ticky from Trade-Ideas. See the FREE profile for SGMO NOW at Trade-Ideas

More details on SGMO:

Sangamo BioSciences, Inc., a clinical stage biopharmaceutical company, focuses on the research, development, and commercialization of zinc finger DNA-binding proteins (ZFPs) for gene regulation and gene modification in the United States. Currently there are 4 analysts that rate Sangamo BioSciences a buy, no analysts rate it a sell, and none rate it a hold.

The average volume for Sangamo BioSciences has been 829,200 shares per day over the past 30 days. Sangamo BioSciences has a market cap of $773.7 million and is part of the health care sector and drugs industry. The stock has a beta of 1.35 and a short float of 17.1% with 8.04 days to cover. Shares are down 13.8% year-to-date as of the close of trading on Wednesday.

If you liked this article you might like

Entry Points Are Tough, and Post-Labor Day Action Is Historically Poor

We're Swimming in a Sea of Green This A.M.

Valeant Higher on Paulson Stake Increase; ImmunoGen Pops; Seattle Genetics Perplexes: Biotech Movers

Shark Bites: Move Along, No Volatility to See Here

Biotech Movers: Sangamo, Epizyme, Revance